• Electra Therapeutics is like a "Genentech for immune-mediated diseases," pioneering a new class of precision antibody therapies to selectively eliminate disease-driving cells.
• Think of them as a highly focused Amgen, developing a novel platform of targeted antibodies designed to act like "smart bombs" for problematic immune cells in conditions ranging from rare autoimmune disorders to certain cancers.

• ipsoprubart: A novel pan-SIRP monoclonal antibody in late-stage clinical development for treating secondary hemophagocytic lymphohistiocytosis (sHLH), designed to selectively deplete pathological myeloid and T cells.
• ELA822: A novel SIRPg-specific monoclonal antibody in early clinical development, designed to selectively deplete activated T cells for potential treatment of chronic T cell-mediated immune and inflammatory diseases.

Electra Therapeutics (ETRA) is a late clinical-stage biopharmaceutical company focused on developing precision medicines for immune-mediated diseases and cancer. Their lead product candidate, ipsoprubart, is currently in a global registrational program, and other candidates are in earlier phases of clinical development.

As Electra Therapeutics' product candidates are still in clinical trials and have not yet received regulatory approval for commercial sale, the company does not currently have major customers from the sale of pharmaceutical products.

If and when their product candidates receive regulatory approval and are commercialized, their primary customers would likely be:

1. Hospitals and clinics: Healthcare institutions that administer or prescribe specialized treatments for conditions like sHLH and T cell/NK cell malignancies.
2. Specialty pharmacies: Pharmacies that dispense high-cost, high-touch medications, often for complex or rare diseases.
3. Pharmaceutical wholesalers and distributors: Companies that manage the logistics and supply chain of approved drugs to healthcare providers and pharmacies.

Ultimately, the medications would be used by individual patients suffering from the diseases they are designed to treat.

Kathy Dong, PharmD, MBA
President, Chief Executive Officer and Director

Kathy Dong has served as President and Chief Executive Officer of Electra Therapeutics since October 2023, bringing broad experience in corporate development, portfolio management, development operations, and product commercialization. Prior to Electra, she was Chief Operating Officer of Star Therapeutics from April 2019 to October 2023, where she was involved in building Electra Therapeutics from the discovery stage into the clinic. Before Star Therapeutics, she served as Vice President of Commercial Development at True North Therapeutics, which was subsequently acquired by Bioverativ (later acquired by Sanofi). She then served as Head of New Product Planning for the complement franchise at Sanofi. Earlier in her career, she spent nine years at Gilead Sciences, where she led the launch and market development of several successful products in Hepatitis B and C.

Chris Clark, CFA
Chief Financial Officer

Chris Clark was promoted to Chief Financial Officer of Electra Therapeutics in August 2026, having joined the company in December 2025 as Executive Vice President, Strategy and Finance. He possesses more than two decades of life sciences investment experience. Before joining Electra, Mr. Clark spent 18 years at RS Investments, a subsidiary of Victory Capital, where he served as a Portfolio Manager and Equity Analyst, focusing on healthcare investments across various fund strategies. He previously worked as a Research Associate at TIAA-CREF, concentrating on global pharmaceutical companies.

Kim-Hien Dao, DO, PhD
Chief Medical Officer

Kim-Hien Dao has served as Chief Medical Officer of Electra Therapeutics since May 2024, having previously been the Vice President, Head of Clinical Development from April 2023. She is a clinician scientist with over 15 years of research experience in academia and biotech. Before joining Electra, she held roles as Senior and Executive Medical Director of Clinical Development at Astex Pharmaceuticals.

Graham Parry, PhD
Chief Scientific Officer

Graham Parry has served as Chief Scientific Officer of Electra Therapeutics since December 2023, bringing over 20 years of experience in developing novel therapies. Prior to Electra, he was Executive Vice President, Translational Sciences, at Star Therapeutics.

Gary S. Koe, PhD
Chief Technical Officer

Gary S. Koe serves as Chief Technical Officer, with over 30 years of experience in biologics Chemistry, Manufacturing, and Controls (CMC). He has led scale-up and quality functions at multiple biopharma companies, including Aravive and Star Therapeutics.

Key Risks to the Business:

1. Clinical Trial Outcomes and Regulatory Approval: Electra Therapeutics' primary business success is contingent on the successful completion of its global registrational program for ipsoprubart, including the SURPASS Phase 2/3 trial in sHLH patients, with enrollment expected to conclude in the second half of 2027. The company also has other product candidates, such as ipsoprubart for T/NK cell malignancies and ELA822, in earlier-stage clinical trials. Failure to achieve favorable clinical trial results (efficacy and safety endpoints), unexpected delays in trial enrollment or completion, or the inability to obtain regulatory approvals from agencies such as the U.S. FDA and European Medicines Agency (EMA) would significantly jeopardize the company's ability to commercialize its product candidates and generate revenue. Despite Breakthrough Therapy and PRIority MEdicine designations, there is no guarantee of regulatory approval.
2. Reliance on Lead Product Candidate: The company’s near-term prospects are heavily dependent on the successful development and commercialization of ipsoprubart, its lead product candidate. While Electra Therapeutics is also advancing ELA822 and has a proprietary library of SIRP-targeted antibodies, these are in earlier stages of development. A significant setback, such as a clinical trial failure, regulatory refusal, or unforeseen safety issues with ipsoprubart, would have a severe adverse impact on the company's financial condition and future prospects, as there are no other late-stage assets ready to quickly fill the void.

• Commercial Launch and Market Penetration of Ipsoprubart for Secondary Hemophagocytic Lymphohistiocytosis (sHLH): Ipsoprubart, Electra's lead product candidate, is currently in a global Phase 2/3 registrational program (SURPASS trial) for newly diagnosed, treatment-naïve sHLH patients. Enrollment in this program is expected to be completed in the second half of 2027. Ipsoprubart has received Breakthrough Therapy designation from the FDA and PRIority MEdicine (PRIME) designation from the EMA, which can expedite regulatory review. Given the lack of broadly approved therapies for sHLH and an estimated growing U.S. patient population, successful regulatory approval and subsequent commercial launch would represent a significant new revenue stream.
• Expansion of Ipsoprubart into T Cell and Natural Killer (NK) Cell Malignancies: Electra is evaluating ipsoprubart as a monotherapy in a Phase 1 clinical trial for patients with relapsed/refractory T cell and NK cell malignancies. Initial data from this trial is anticipated in the second half of 2027. Positive results and further development in this area could open up new, substantial market segments for ipsoprubart, building on encouraging anti-tumor activity observed in earlier studies involving sHLH patients with underlying lymphomas. The company estimates a diagnosed incidence rate of over 13,000 annually in the U.S. across these malignancy subtypes.
• Advancement of ELA822 into Patient Studies for T Cell-Mediated Immune and Inflammatory Diseases: ELA822, Electra's second product candidate, is a novel SIRPg-specific monoclonal antibody designed to selectively deplete activated T cells. A Phase 1 clinical trial in healthy volunteers was initiated in August 2026, with data expected in the first half of 2027. The company plans to initiate a Phase 1/2 clinical trial in patients with T cell-mediated immune disorders in mid-2027. Successful progression of ELA822 through these clinical stages would validate Electra's proprietary SIRP-targeted antibody platform and establish a second potential revenue-generating asset for chronic immune and inflammatory diseases.

Share Issuance

• Electra Therapeutics completed a Series B Preferred Stock financing in February 2022.

Inbound Investments

• Electra Therapeutics received a Series B Preferred Stock financing in February 2022.
• The company was originally incorporated in October 2018 as a wholly-owned subsidiary of Star Therapeutics LLC.